MRI in prostate cancer diagnosis
MRI before biopsy and in screening for prostate cancer.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 52, 74, 70, 65, 81.
New guidelines and consensus this year
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative IntentEur Urol2026 Sep
- Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026)J Urol2026 May
- The Italian Society of Urology Statement on focal therapy for localized prostate cancerMinerva Urol Nephrol2026 Feb
- French recommendations from the AFU Cancer Committee for prostate cancer: 2025 summary of changesFr J Urol2025 Dec
All papers from the last 12 months
951 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Multimodality imaging of high-grade prostate adenocarcinoma with diffusion MRI, PSMA PET and dual-layer spectral CT: A case reportRadiol Case Rep2026 DecPMID 42781221
- Effect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancerInt J Hyperthermia2026 DecPMID 42733361
- Present status of prostate cancer diagnosis, limitations, challenges, and future endeavorsAnn Med2026 DecPMID 42544420Review
- Prostate cancer: Value of the PI-FAB score and volume-adjusted PSA density in recurrence assessment after HIFUEur J Radiol Open2026 DecPMID 42388516
- Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS and PSA double gray zoneAdipocyte2026 DecPMID 42231146
- Near-complete Response of Bilateral Adrenal Metastases to 177Lu-PSMA Therapy in Castration-resistant Prostate Cancer on Posttherapeutic SPECT-CT Follow UpClin Nucl Med2026 Nov 1PMID 42853992
- From negative bone scintigraphy to oncologic superscan within five months: Explosive PSA kinetics in grade group 5 prostate adenocarcinomaUrol Case Rep2026 NovPMID 42835955
- PRECISE Assessment of Sequential Biparametric MRI and Clinically Significant Prostate Cancer in Biopsy-naive Men: A Retrospective Cohort StudyEur Urol Open Sci2026 NovPMID 42831142
- Natural History of PI-RADS 3 Lesions on Serial Prostate mpMRIProstate2026 NovPMID 42641045
- Comparison of Whole-Gland and Transition Zone PSA Density in Predicting Clinically Significant Prostate Cancer in PI-RADS 3 LesionsProstate2026 NovPMID 42633675
More urology trends
All specialties →Minimally invasive BPH treatments
Water vapour therapy, urethral lift, aquablation and prostatic artery embolisation.
Antibody-drug conjugates in bladder cancer
Enfortumab vedotin and other ADCs in urothelial cancer.
Key point: Enfortumab vedotin-related adverse events, particularly cutaneous toxicity, were associated with favorable clinical outcomes, but findings are hypothesis-generating and need prospective confirmation.
Transperineal prostate biopsy
Biopsy through the perineum instead of the rectum.
Key point: Transperineal biopsy is the recommended approach when technically feasible.
Thulium fibre laser
Thulium fibre laser for stone lithotripsy and prostate surgery.
Key point: ThuFLEP and conventional HoLEP are clinically comparable, with no definitive superiority of either laser.
PSMA PET in prostate cancer
PSMA PET imaging for staging and recurrence of prostate cancer.
Key point: PSMA-PET/CT is recommended only when PSA exceeds 0.2 μg/L, reporting should follow PSMA-RADS, and it is preferred over lymph-node dissection for staging.
Male infertility
Male infertility and trends in semen quality.
Key point: Male infertility management should be couple-centered, integrating the female partner's reproductive timeline to avoid preventable delays in effective therapy.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
prostate[tiab] AND (MRI[tiab] OR "magnetic resonance"[tiab]) AND (screening[tiab] OR biopsy[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.